However, little is known about the differential and/or overlapping effects between sGC stimulators and activators on neuroprotection and synaptic plasticity, and the implications for neurodegenerative diseases with a deficient NO–sGC–cGMP signalling system such as Alzheimer’s disease and vascular dementia7,17–19. Here, SGCB is linked to early-onset autosomal dominant Alzheimer disease.